How to cite this article: Downs J, Géranton SM, Bebbington A, Jacoby P, Bahi-Buisson N, Ravine D, Leonard H. 2010. Linking MECP2 and pain sensitivity: The example of Rett syndrome. Am J Med Genet Part A 152A:1197–1205.
Linking MECP2 and pain sensitivity: The example of Rett syndrome†
Article first published online: 13 APR 2010
Copyright © 2010 Wiley-Liss, Inc.
American Journal of Medical Genetics Part A
Volume 152A, Issue 5, pages 1197–1205, May 2010
How to Cite
Downs, J., Géranton, S. M., Bebbington, A., Jacoby, P., Bahi-Buisson, N., Ravine, D. and Leonard, H. (2010), Linking MECP2 and pain sensitivity: The example of Rett syndrome. Am. J. Med. Genet., 152A: 1197–1205. doi: 10.1002/ajmg.a.33314
- Issue published online: 22 APR 2010
- Article first published online: 13 APR 2010
- Manuscript Accepted: 6 DEC 2009
- Manuscript Received: 15 JUL 2009
- International Rett Syndrome Foundation (IRSF)
- National Institutes of Health. Grant Number: 5R01HD043100-05
- National Medical and Health Research Council (NHMRC) project grant. Grant Number: #303189
- NHMRC program grant. Grant Number: #353514
- NHMRC Senior Research Fellowship. Grant Number: #572568
- pain insensitivity;
- Rett syndrome
Recent animal studies suggest links between MeCP2 function and sensitivity to pain. This study investigated the nature and prevalence of atypical pain responses in Rett syndrome and their relationships with specific MECP2 mutations. Families enrolled in the Australian Rett Syndrome Database (ARSD) and InterRett database participated in this study. Cases with a known MECP2 pathogenic mutation, whose families had completed a questionnaire on registration and had answered questions on pain sensitivity were included (n = 646). Logistic regression was used to analyze relationships between the atypical pain responses and genotype. Descriptions of decreased pain sensitivity were content analyzed. The prevalence estimate of reporting an abnormal pain response was 75.2% and a decreased sensitivity to pain was 65.0% in the population-based ARSD. Families of ARSD and InterRett subjects with a C-terminal (OR 2.6; 95% CI 0.8–8.0), p.R168X (OR 2.1; 95% CI 0.7–6.1), or p.R306C (OR 2.7; 95% CI 0.8–9.6) mutation were more likely to report decreased sensitivity to pain. Parents and carers described decreased and delayed responses in situations judged likely to cause pain such as injections, falls, trauma, and burns. This study has provided the first precise estimate of the prevalence of abnormal sensitivity to pain in Rett syndrome but specific relationships with genotype are not yet clear. Clinical practice should include a low threshold for the clinical assessment of potential injuries in Rett syndrome. © 2010 Wiley-Liss, Inc.